In one paragraphArticle in HemaSphere, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
17 authors.
Hishan TharmaseelanFaculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), and German Hodgkin Study Group (GHSG) University of Cologne Cologne Germany.ORCID https://orcid.org/0009-0002-5680-8714 Janina JablonskiFaculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), and German Hodgkin Study Group (GHSG) University of Cologne Cologne Germany.ORCID https://orcid.org/0009-0007-2811-4762 Susan K ParsonsDivision of Hematology/Oncology and Institute for Clinical Research and Health Policy Studies Tufts Medical Center Boston Massachusetts United States of America.
Angie Mae RoddayDivision of Hematology/Oncology and Institute for Clinical Research and Health Policy Studies Tufts Medical Center Boston Massachusetts United States of America.
Alexander FossåDepartment of Oncology Oslo University Hospital Oslo Norway.
Mark HertzbergDepartment of Haematology Prince of Wales Hospital Sydney New South Wales Australia.
Martin FehrSwiss Cancer Institute Competence Center Bern Switzerland.
Richard GreilAustrian Group for Medical Tumor Therapy (AGMT) Salzburg Austria.
Michael FuchsFaculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), and German Hodgkin Study Group (GHSG) University of Cologne Cologne Germany.ORCID https://orcid.org/0000-0003-3289-3272 Helen KaulFaculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), and German Hodgkin Study Group (GHSG) University of Cologne Cologne Germany.
Peter BorchmannFaculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), and German Hodgkin Study Group (GHSG) University of Cologne Cologne Germany.ORCID https://orcid.org/0000-0003-3782-2158 Justin FerdinandusFaculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), and German Hodgkin Study Group (GHSG) University of Cologne Cologne Germany.ORCID https://orcid.org/0000-0002-3481-7997 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Identifiers
PMID42730067
PMCPMC13567801
What OpenQuestion holds
Textmetadata
Read underepoch 390